DK3463432T3 - Flydende neurotoksin-formulering stabiliseret med tryptofan eller tyrosin - Google Patents

Flydende neurotoksin-formulering stabiliseret med tryptofan eller tyrosin Download PDF

Info

Publication number
DK3463432T3
DK3463432T3 DK17728095.5T DK17728095T DK3463432T3 DK 3463432 T3 DK3463432 T3 DK 3463432T3 DK 17728095 T DK17728095 T DK 17728095T DK 3463432 T3 DK3463432 T3 DK 3463432T3
Authority
DK
Denmark
Prior art keywords
tryptophan
tyrosine
formulation stabilized
neurotoxin formulation
liquid
Prior art date
Application number
DK17728095.5T
Other languages
English (en)
Inventor
Anders Jarstad
Anna Friis
Ulf Stahl
Barbro Agren
Emilia Edstrom
Ann Gurell
Andrew Pickett
Original Assignee
Ipsen Biopharm Ltd
Nestle Skin Health Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd, Nestle Skin Health Sa filed Critical Ipsen Biopharm Ltd
Application granted granted Critical
Publication of DK3463432T3 publication Critical patent/DK3463432T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17728095.5T 2016-05-27 2017-05-26 Flydende neurotoksin-formulering stabiliseret med tryptofan eller tyrosin DK3463432T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016062085 2016-05-27
PCT/EP2017/062785 WO2017203038A1 (en) 2016-05-27 2017-05-26 Liquid neurotoxin formulation stabilized with tryptophan or tyrosine

Publications (1)

Publication Number Publication Date
DK3463432T3 true DK3463432T3 (da) 2021-01-04

Family

ID=56289455

Family Applications (3)

Application Number Title Priority Date Filing Date
DK20152386.7T DK3679946T3 (da) 2016-05-27 2017-05-26 Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin
DK21211390.6T DK4026532T3 (da) 2016-05-27 2017-05-26 Flydende neurotoxinformulering stabiliseret med tryptophan eller tyrosin
DK17728095.5T DK3463432T3 (da) 2016-05-27 2017-05-26 Flydende neurotoksin-formulering stabiliseret med tryptofan eller tyrosin

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK20152386.7T DK3679946T3 (da) 2016-05-27 2017-05-26 Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin
DK21211390.6T DK4026532T3 (da) 2016-05-27 2017-05-26 Flydende neurotoxinformulering stabiliseret med tryptophan eller tyrosin

Country Status (32)

Country Link
US (5) US20190183988A1 (da)
EP (3) EP4026532B1 (da)
JP (1) JP7053498B2 (da)
KR (2) KR102423739B1 (da)
CN (2) CN109562148A (da)
AR (1) AR108631A1 (da)
AU (1) AU2017270359B2 (da)
CA (1) CA3025437A1 (da)
CY (2) CY1124237T1 (da)
DK (3) DK3679946T3 (da)
EA (1) EA038124B1 (da)
ES (3) ES2846350T3 (da)
FI (1) FI4026532T3 (da)
GE (2) GEAP202014939A (da)
HR (3) HRP20251606T1 (da)
HU (2) HUE052023T2 (da)
IL (2) IL285190B (da)
LT (3) LT4026532T (da)
MX (1) MX392529B (da)
NZ (1) NZ788585A (da)
PL (3) PL4026532T3 (da)
PT (3) PT3679946T (da)
RS (3) RS67508B1 (da)
RU (1) RU2741497C9 (da)
SA (1) SA518400513B1 (da)
SG (1) SG11201810561YA (da)
SI (3) SI3679946T1 (da)
SM (3) SMT202200080T1 (da)
TW (1) TWI777955B (da)
UA (1) UA123679C2 (da)
WO (1) WO2017203038A1 (da)
ZA (1) ZA201807904B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2009332947C1 (en) 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
EP2445521A4 (en) 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
US20190185837A1 (en) * 2017-12-20 2019-06-20 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders
UY38744A (es) * 2019-06-07 2020-12-31 Nestle Skin Health S A Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
CN115397399B (zh) * 2020-04-08 2025-06-27 玫帝托克斯股份有限公司 一种易于控制排出速度且稳定的肉毒杆菌毒素预填充式注射器剂型
CN116440281A (zh) * 2022-01-07 2023-07-18 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物
CA3241558A1 (en) 2022-01-14 2023-07-20 Eva AXEN Treatment of moderate to very severe glabellar lines and lateral canthal lines
EP4479023A1 (en) * 2022-02-15 2024-12-25 Merz Pharma GmbH & Co. KGaA Liquid botulinum toxin formulation and use thereof
WO2025032220A1 (en) 2023-08-10 2025-02-13 Merz Pharma Gmbh & Co. Kgaa Liquid botulinum toxin formulation and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
ATE519494T1 (de) * 2000-02-08 2011-08-15 Allergan Inc Pharmazeutische zusammensetzungen mit botulinum- toxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
AU2001236005A1 (en) * 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
US6627602B2 (en) * 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
BRPI0513850A (pt) 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
ES2526913T3 (es) * 2004-08-04 2015-01-16 Ipsen Biopharm Limited Composición farmacéutica que contiene neurotoxina 2 botulínica
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US8617568B2 (en) 2007-07-10 2013-12-31 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
WO2011038015A1 (en) 2009-09-24 2011-03-31 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
KR101910490B1 (ko) 2011-06-01 2018-10-22 바이오메디슨, 인코퍼레이티드 비-ｆｒｅｔ 보툴리눔 검정법
HUE037509T2 (hu) 2011-09-29 2018-09-28 Cellsnap Llc Készítmények és eljárások toxigenicitás meghatározására
KR101357999B1 (ko) * 2012-03-20 2014-02-03 함종욱 보툴리눔 에이형 독소의 액상제품
WO2015044416A1 (en) 2013-09-30 2015-04-02 Galderma S.A. Prostate cancer treatment
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins

Also Published As

Publication number Publication date
LT3679946T (lt) 2022-02-10
US20210330765A1 (en) 2021-10-28
LT4026532T (lt) 2026-01-12
WO2017203038A1 (en) 2017-11-30
MX2018014631A (es) 2019-06-12
RS67508B1 (sr) 2025-12-31
JP7053498B2 (ja) 2022-04-12
SMT202200080T1 (it) 2022-03-21
RU2741497C2 (ru) 2021-01-26
RS62832B1 (sr) 2022-02-28
EP3463432A1 (en) 2019-04-10
AR108631A1 (es) 2018-09-12
KR102399451B1 (ko) 2022-05-23
PL4026532T3 (pl) 2026-03-16
DK3679946T3 (da) 2022-02-07
HRP20202070T1 (hr) 2021-02-19
HUE052023T2 (hu) 2021-04-28
ES3062544T3 (en) 2026-04-13
GEAP202014939A (en) 2020-04-10
TW201742632A (zh) 2017-12-16
KR20220054887A (ko) 2022-05-03
RU2018142149A (ru) 2020-06-29
ZA201807904B (en) 2020-05-27
ES2846350T3 (es) 2021-07-28
FI4026532T3 (fi) 2026-02-03
SG11201810561YA (en) 2018-12-28
US12285468B2 (en) 2025-04-29
IL263173B (en) 2021-08-31
LT3463432T (lt) 2021-01-25
EP4026532B1 (en) 2025-11-26
EA038124B1 (ru) 2021-07-09
RU2741497C9 (ru) 2021-04-30
US20230181702A1 (en) 2023-06-15
GEP20207139B (en) 2020-07-27
EP3679946A1 (en) 2020-07-15
CN109562148A (zh) 2019-04-02
EP3463432B1 (en) 2020-10-07
CN111701010A (zh) 2020-09-25
HRP20251606T1 (hr) 2026-02-13
AU2017270359B2 (en) 2023-09-21
PT3463432T (pt) 2021-01-12
CN111701010B (zh) 2023-09-26
MX392529B (es) 2025-03-21
IL285190B (en) 2022-07-01
JP2019517481A (ja) 2019-06-24
SA518400513B1 (ar) 2022-11-03
BR112018074311A2 (pt) 2019-10-01
US20190183988A1 (en) 2019-06-20
EA201892493A1 (ru) 2019-04-30
IL285190A (en) 2021-08-31
EP3679946B1 (en) 2022-01-05
PL3679946T3 (pl) 2022-05-30
CY1124916T1 (el) 2023-01-05
CA3025437A1 (en) 2017-11-30
NZ748626A (en) 2025-05-02
KR20190022548A (ko) 2019-03-06
US20230190892A9 (en) 2023-06-22
KR102423739B1 (ko) 2022-07-21
PL3463432T3 (pl) 2021-04-19
EP4026532A1 (en) 2022-07-13
HUE057640T2 (hu) 2022-05-28
RU2018142149A3 (da) 2020-07-23
SI3463432T1 (sl) 2021-02-26
DK4026532T3 (da) 2025-12-08
AU2017270359A1 (en) 2018-12-13
SI4026532T1 (sl) 2026-01-30
SI3679946T1 (sl) 2022-04-29
CY1124237T1 (el) 2022-07-22
TWI777955B (zh) 2022-09-21
SMT202100003T1 (it) 2021-03-15
US20250255943A1 (en) 2025-08-14
PT4026532T (pt) 2026-02-03
SMT202500479T1 (it) 2026-01-12
PT3679946T (pt) 2022-01-14
HRP20220024T1 (hr) 2022-04-01
NZ788585A (en) 2025-12-19
ES2911124T3 (es) 2022-05-17
RS61340B1 (sr) 2021-02-26
UA123679C2 (uk) 2021-05-12
US20240050539A1 (en) 2024-02-15
IL263173A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
DK4026532T3 (da) Flydende neurotoxinformulering stabiliseret med tryptophan eller tyrosin
HUE053889T2 (hu) Folyadék áramlását korlátozó eszköz
DK3370828T3 (da) Oximforbindelse som agonister af muscarin m1- og/eller m4- receptoren
DK3727453T3 (da) Flydende sammensætning til administration
DK3127300T3 (da) Håndtering af nic-krypterede flows til at migrere gæster eller opgaver
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
PT3334747T (pt) Formulação de gonadotrofina líquida estável
DK3532029T3 (da) Flydende farmaceutisk sammensætning
EP3558000C0 (en) COMPOSITIONS CONTAINING ACETIC ACID AND HYPOCHLOROUS ACID
DK3014279T3 (da) Fremgangsmåde til bestemmelse af proteinaggregater under anvendelse af overflade-fida
DK3217963T3 (da) Fremgangsmåder til behandling af individer med prader-willis syndrom eller smith-magenis syndrom
EP3530264A4 (en) OIL-IN-WATER-TYPE EMULSION COMPOSITION
DK3535050T3 (da) Væskeblandingssystem med vertikalt justerbart blandeelement samt anvendelsesfremgangsmåde
LT3419595T (lt) Stabili skysta gonadotropino kompozicija
DK3742164T3 (da) Indretning til bestemmelse af tilstedeværelsen og/eller mængden af målmolekyler
DK3534002T3 (da) Væskepumpe
HUE055016T2 (hu) Olaj-a-vízben nanoemulziós klobetazol készítmény
DK3330267T3 (da) Salt af quinazolinderivat eller crystal deraf samt fremgangsmåde til fremstilling af salt af quinazolinderivat eller crystal deraf
DK3380487T3 (da) Additivsystemer til anvendelse i proteinpegylering
DK3704328T3 (da) Flydende gulv
EP3554483C0 (en) REDUCTION OF SIDE EFFECTS OF SHORT-ACTING NO DONORS
EP3305296A4 (en) AQUEOUS LIQUID FORMULATION
FI20155198L (fi) Aurinkokäyttöinen fluidipumppu ja siihen liittyvä järjestely
ES1113430Y (es) "paleta ligera para pintura, conservacion y restauracion de obras de arte"
EP3562512A4 (en) FORMULATION FOR THE STABILIZATION OF THERAPEUTIC BIOLOGICAL AGENTS